Q-omics provides the consensus-scored TRAJ49 profile across patient tissues and cancer cell-line models. TRAJ49 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TRAJ49 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, TRAJ49 RNA expression shows 11,144 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, COAD, and THYM as cancer lineages where TRAJ49 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ49 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ49 survival associations across molecular data types. TRAJ49 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ49 RNA expression–survival associations across cancer types. High TRAJ49 expression shows unfavorable associations in ESCA, but favorable associations in SKCM, LUAD, KIRC, BLCA and CHOL. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify SKCM as the clearest survival context for TRAJ49 RNA expression.
This table summarizes TRAJ49 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in READ for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ49. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ49 shows lower tumor expression in COAD and READ and higher tumor expression in KIRC. The COAD box plot shows higher TRAJ49 RNA expression in normal versus tumor tissue (log2 FC = −1.381, t-test p = .002).
This table shows molecular features associated with TRAJ49 in patient tissues and cancer cell lines. In patient samples, TRAJ49 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
